Identification of yeast and sensitivity in vitro against different antifungal;Identificacion de levaduras y sensibilidad in vitro a diversos antifungicos

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 18, Issue 3, 2000, Pages 120-124

  Muriel, María Aurora ^a   Vizcaíno, María José ^a   Bilbao, Rafael ^b   Herruzo, Rafael ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antifungal; Candida; Yeasts

Indexed keywords

AMPHOTERICIN B; FLUCYTOSINE; ANTIFUNGAL AGENT;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CHEMOSENSITIVITY; FUNGUS IDENTIFICATION; IN VITRO STUDY; YEAST; ADULT; ANTIBIOTIC RESISTANCE; CANDIDA; DRUG EFFECT; FEMALE; HUMAN; INTENSIVE CARE UNIT; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; NEWBORN; THRUSH; VAGINA CANDIDIASIS;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, ORAL; CANDIDIASIS, VULVOVAGINAL; DRUG RESISTANCE, MICROBIAL; FEMALE; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS;

EID: 0034153097     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Vaqué J y grupo de trabajo EPINE. Evolución de la prevalencia de las infecciones nosocomiales en los hospitales españoles. Sociedad Española de Medicina Preventiva, Salud Pública e Higiene; 1990-197: 250-251, 262-263, 296-297, 302-309 y 318-319.
2. Arzeni D, del Poeta M, Simonetti O, Offidani AM, Lamura L, Balducci M et al. Prevalence and antifungal susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy. Eur J Epidemiol 1997; 13: 447-450.
3. Herruzo Cabrera R, de Lope C, Fernández Arjona M, Rey Calero J. Risk factors of infection and digestive tract colonization by Candida spp. in a neonatal intensive care unit. Eur J Epidemiol 1995; 11: 291-295.
4. Nolla Salas J, Sitges Serra A, León Gil C, Martínez González J, León Regidor MA, Ibéñez Lucía P et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med 1997; 23: 23-30.
5. Vázquez JA, Dembry LM, Sánchez V, Vázquez MA, Sobel JD, Dmuchowski C et al. Nosocomial C. glabrata colonization: an epidemiologic study. J Clin Microbiol 1998; 36: 421-426.
6. Baquero F. Antifúngicos: la nueva frontera. Rev Esp Quimioterapia 1998; 11: 187-188.
7. Martínez MM, Mendaza P, Daza RM, Sánchez G, Martín P, Martín JE et al. Estudio de la sensibilidad in vitro de levaduras por el sistema ATB-Fungus. Rev Esp Quimioterapia 1998; 11:251-253.
8. Odds FC, Bernaerts R. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol 1994; 32: 1923-1929.
9. Davey KG, Chant PM, Downer CS, Campbell CK, Warnock DW. Evaluation of the AUXACOLOR system, a new method of clinical yeast identification. J Clin Pathol 1995; 48: 807-809.
10. Davey KG, Holmes AD, Johnson EM, Szekely A, Warnock DW. Comparative evaluation of FUNGITEST and broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans. J Clin Microbiol 1998; 36: 926-930.
11. García-Martos P, Mira Gutiérrez J. Evaluación de cuatro medios de cultivo para la diferenciación e identificación de levaduras. Rev Diagn Biol 1996; 45: 208-211.
12. Dúo B, Arévalo JM, Abecia LC. Susceptibilidad de 40 cepas de Candida albicans a cinco antifúngicos azólicos. Rev Diagn Biol 1998; 47: 217-222.